Testing effectiveness (Phase 2)Active Not RecruitingNCT06400251
What this trial is testing
Testing Ipatasertib as Potentially Targeted Treatment in Cancers With AKT Genetic Changes (MATCH - Subprotocol Z1K)
Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmRefractory Lymphoma+2 more
National Cancer Institute (NCI) 35